Journal
NEUROLOGY
Volume 76, Issue 14, Pages 1256-1262Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182143537
Keywords
-
Categories
Funding
- Michael J Fox Foundation
- NIH [RR026315-02]
- Medtronic, Inc.
- Allergan, Inc.
- Cleveland Medical Devices Inc.
- Davis Phinney Foundation
- Michael J. Fox Foundation
- Teva Pharmaceutical Industries Ltd.
- Solvay Pharmaceuticals
- Inc./Abbott
- US Department of Veterans Affairs
- Amarin Corporation
- Boehringer Ingelheim
- GlaxoSmithKline
- Pfizer Inc.
- Merck Serono
- Novartis
- UCB
- Curry Rockefeller Group
- Cephalon, Inc.
- Merz Pharmaceuticals, LLC
- Michael J. Fox Foundation for Parkinson Research
- Parkinson Study Group
- Gardner Family Center for Parkinson's Disease and Movement Disorders
Ask authors/readers for more resources
Background: There is a paucity of therapies for gait impairment in Parkinson disease (PD). Open-label studies have suggested improved gait after treatment with methylphenidate (MPD). Objective: To evaluate the efficacy of MPD for the treatment of gait impairment in PD. Methods: Twenty-seven subjects with PD and moderate gait impairment were screened for this 6-month placebo-controlled, double-blind study. Subjects were randomly assigned to MPD (maximum, up to 80 mg/day) or placebo for 12 weeks and crossed over after a 3-week washout. The primary outcome measure was change in a gait composite score (stride length + velocity) between groups at 4 and 12 weeks. Secondary outcome measures included changes in motor function, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), Freezing of Gait Questionnaire (FOGQ), number of gait-diary freezing episodes, and measures of depression, sleepiness, and quality of life. Three-factor repeated-measures analysis of variance was used to measure changes between groups. Results: Twenty-three eligible subjects with PD were randomized and 17 completed the trial. There was no change in the gait composite score or treatment or time effect for any of the variables. Treatment effect was not modified by state or study visit. Although there was a trend for reduced frequency of freezing and shuffling per diary, the FOGQ and UPDRS scores worsened in the MPD group compared to placebo. There was a marginal improvement in some measures of depression. Conclusions: MPD did not improve gait and tended to worsen measures of motor function, sleepiness, and quality of life. Classification of evidence: This study provides Class III evidence for the lack of benefit of MPD on PD-associated gait impairment. Clinical trial registration: NCT00526630. Neurology (R) 2011; 76: 1256-1262
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available